[Form 4] ALX Oncology Holdings Inc. Insider Trading Activity

Rhea-AI Filing Summary

Curran Daniel J., a director of ALX Oncology Holdings Inc. (ALXO), acquired a stock option grant for 40,400 shares on 08/12/2025. The option carries an exercise price of $0.615 and an expiration date of 08/11/2035. According to the filing, the shares subject to the option vest in 36 equal monthly installments beginning on September 12, 2025.

The Form 4 was filed by one reporting person and signed under power of attorney on 08/13/2025. The transaction is recorded as an acquisition of a derivative security whose underlying title is common stock; the ownership is reported as direct.

Insights

Financial Analyst

TL;DR: Director Curran was granted 40,400 stock options at $0.615 on 08/12/2025; vesting over 36 months; filing reports direct ownership.

The Form 4 discloses an acquisition (A) of a stock option covering 40,400 shares with an exercise price of $0.615 and an expiration date of 08/11/2035. Vesting is specified as 36 equal monthly installments beginning September 12, 2025. The report was filed by a single reporting person and executed under power of attorney on 08/13/2025. No dispositions, cash proceeds, or other compensatory arrangements are reported in this filing.

Corporate Governance Expert

TL;DR: The filing documents a director option grant (40,400 options) with a multi-year vesting schedule and direct beneficial ownership.

The Form 4 shows Curran Daniel J. receiving a stock option on 08/12/2025 for 40,400 underlying shares, exercisable at $0.615 and expiring 08/11/2035, with vesting in 36 equal monthly installments starting September 12, 2025. The filing is recorded as an acquisition and lists direct ownership. The form was signed by a power of attorney on 08/13/2025. The document contains no additional governance disclosures or changes to board or officer roles.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Curran Daniel J.

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$0.615	08/12/2025		A		40,400		(1)	08/11/2035	Common Stock	40,400	$0	40,400	D

Explanation of Responses:

1. Shares subject to the option vest in 36 equal monthly installments beginning on September 12, 2025.

	/s/ Shelly Pinto, by power of attorney	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.